Abstract
We have studied the mechanism of steroid-induced osteonecrosis by examining the effect of dexamethasone on a multipotential cell line, D1, which is derived from bone marrow and is capable of differentiating into either the osteoblast or the adipocyte lineage. The expression of bone cell and fat cell transcription factors Cbfa1/Runx2 and PPARγ2, were determined. Osteocalcin promoter activity was measured by co-transfecting the cells with the phOC-luc and pSV β-Gal plasmids. Dexamethasone increased PPARγ2 gene expression 2-fold, while Cbfa1/Runx2 gene expression and osteocalcin promoter activity decreased by 50–60%, and VEGF protein, measured by ELISA, decreased by 55%. These changes indicate enhanced adipogenesis and decreased osteogenesis by mesenchymal cells in vitro, together with a decrease in VEGF, a potent angiogeneic factor, suggesting that dexamethasone may shunt uncommitted osteoprogenitor cells in marrow from osteoblastic differentiation into the adipocytic pathway, leading to diminished vascularization and eventual osteonecrosis.
Similar content being viewed by others
Introduction
The association between steroid administration and the development of osteonecrosis has been well established since 1957. However, the precise pathogenesis of osteonecrosis remains unknown [1,2]. Investigations on the mechanism underlying the pathogenesis of osteonecrosis have so far focused on either diminished blood supply to bone or marrow cell differentiation [3,4,5]
The pathobiological mechanism underlying the induction of adipogenesis and suppression of osteogenesis by steroids has not been elucidated, to our knowledge. In our initial report [6], we demonstrated that dexamethasone stimulates bone marrow mesenchymal cell differentiation into adipocytes as well as the accumulation of fat in the marrow while suppressing cell differentiation into osteoblasts; nevertheless, the mechanism is still not clear. It is likely that interconversion of stromal cells among phenotypes, as well as commitment to a particular lineage with suppression of alternative phenotypes, is governed by specific transcription factors [7,8]. Indeed, core binding factor a1/Runt-related transcription factor-2 (Cbfa1/Runx2) is a transcription factor that is required to commit mesenchymal progenitors to the osteoblast lineage [9,10,11,12]. Mice that are deficient in this factor lack osteoblasts and mineralized bone matrix [12]. Expression of Cbfa1/Runx2 in fibroblastic cells induces transcription of osteoblast specific factors [13]. By contrast, peroxisome proliferator activated receptor γ2 (PPARγ2) gene expression destines cells for adipocyte differentiation [14,15]. Transfection of fibroblastic cells with PPARγ2 and subsequent activation with an appropriate ligand causes the development of adipocytes, supporting the idea that PPARγ2 plays a crucial role in the differentiation of mesenchymal cells to adipocytes [16]. The effect of dexamethasone on cell differentiation through its influence on transcription factors needs to be elucidated.
Meanwhile, many authors have suggested that interference with the blood supply, by various means, plays a major role in the pathogenesis of osteonecrosis [2,17]. Intraosseous hypertension [18], intravascular fat emboli and coagulation [19,20] compression of vessels by progressive accumulation of marrow fat stores [21] and coagulopathies are commonly accepted theories. Such theories have focused on decreased blood supply as the underlying factor for osteonecrosis. There are few reports on the angiogenic changes that ensue upon treatment of mesenchymal cells with dexamethasone; however, normal and pathological bone physiology is inexorably tied to angiogenesis [22]. There are several indications that vasculature plays an important role for the mechanism of coupling resorption by osteoclasts and bone formation by osteoblasts [23]. There is a functional relationship between bone endothelium and osteoblasts, although the mechanism is not clear. Recent reports document the important role of angiogenic factors in skeletal development and in disorders of the skeleton. The process of bone development and repair depends on adequate formation of new capillaries from existing blood vessel [24]. Angiogenesis, the development of a microvascular network for blood supply, is critical for the development, remodeling, and healing of most tissues, including bone [24,25,26,27]. Vascular endothelial growth factor (VEGF), a dimeric heparin-binding glycoprotein, plays a central role in the development and modulation of angiogenesis and has been studied extensively; moreover, VEGF–mediated angiogenesis is important in fracture repair [28] and endochondral ossification [29]. Thus, it appeared promising to investigate the role of angiogenic factors, specifically VEGF, in osteoporosis and osteonecrosis.
Understanding the effects of dexamethasone on bone and fat cell transcription factors, and changes in VEGF during mesenchymal cell differentiation, are clearly important in order to elucidate the mechanism of steroid induced osteonecrosis. This study was designed in an attempt to answer two questions. First, do steroids induce adipogenesis and suppress osteogenesis by regulating transcription factors PPARγ2 and Cbfa1/Runx2? Second, will steroid decrease angiogenesis by decreasing VEGF expression? We examined the effect of dexamethasone on a multipotential bone marrow cell line, D1, which was previously cloned from mouse bone marrow stroma and shown to produce a mineralized matrix as well as adipogenesis in vivo [30]. The treatment of D1 cells with dexamethasone in vitro showed diminished gene expression for Cbfa1/Runx2, and an increase in PPARγ2, consistent with inhibition of osteogenesis and enhanced adipogenesis in vitro. In addition, VEGF production was suppressed upon treatment of mesenchymal cells with dexamethasone in vitro.
Materials and methods
Steroid induced adipogenesis in culture
Multipotential mesenchymal cells, D1, which were cloned from Balb/c mouse bone marrow cells, were maintained in Dulbecco’s Modified Eagle’s Medium (Gibco BRL, Gaithersburg, Md., USA) containing 10% fetal bovine serum (Hyclone Laboratories, Logan, Vt., USA), 50 μg/ml sodium ascorbate, and 100 IU/ml penicillin G and 100 μg streptomycin per ml of culture media, in a humidified atmosphere of 5% carbon dioxide at 37°C. For all experiments, cells were seeded at a density of 5×103 cells per cm2 and the experiments were started when the cells reached 80% confluence.
D1 cells were treated with five different concentrations of dexamethasone (Sigma Chemical Company, St Louis, Mo., USA) between 10−9 and 10−5 mol/l. Cell morphology and the appearance of cytoplasmic lipid droplets were monitored with a phase contrast microscope. To determine the number of adipocytes, cells in culture were stained with Sudan IV, a stain for fat, counterstained with hematoxylin, and scanned using a Nikon 35 mm slide scanner (Nikon Inc., Melville, N.Y., USA).
Semiquantitative RT-PCR
Semiquantitative RT-PCR was carried out according to the Ambion (Ambion, Austin, Tex., USA) protocol based on the Competimer Technique. This method has been validated to be semiquantitative with data that has correlation coefficients of –0.97 [8,31]. By mixing primers for 18S rRNA with Ambion’s exclusive competimers (primers of the same sequence but that cannot be extended), the 18S rRNA signal can be reduced even to the level of rare messages. It provides semiquantitative data on relative changes of a given mRNA when amplified with the optimal ratio of 18S primers:competimers for a fixed number of PCR cycles within the liner range [32]. RNA (0.5 μg) was reverse transcribed in 20 μl buffer containing AMV reverse transcriptase 5×2.5 μmol/l poly dT, 1 mmol/l each of dATP, dCTP, dGTP, dTTP, 20 IU of RNAse inhibitor, and 20 IU of AMV RT. The reverse transcription reaction was incubated at room temperature for 10 min and then in a Perkin-Elmer Cetus DNA Thermal Cycler at 42°C for 15 min, 99°C for 5 min, and then at 5°C for 5 min. Aliquots of cDNA were amplified in a 100 μl PCR reaction mixture which contained 0.3 μmol/l of 5’ and 3’ oligoprimers, in high-fidelity PCR buffer containing 15 mmol/l MgCl2, 0.1 nmol/l each of dATP, dCTP, dGTP, and dTTP, 0.35 IU of high-fidelity Taq DNA polymerase. For each cDNA sample, PCR amplification was performed in triplicate. The identity of PCR products was confirmed by sequence analysis in an automated DNA sequencer (Perkin-Elmer, Norwalk, Conn., USA).
The primer sequences for PCR were: for Cbfa1/Runx2: mCbfa1/Runx2 +515.F-5’ACG ACA ACC GCA CCA TGG T-3’; mCbfa1/Runx2 +1382.R-5’CGG CTC TCA GTG AGG GAT G-3’; for PPARγ2: mPPARγ2+1111.F-5’CTG GCC TCC CTG ATG AAT AA-3’; mPPARγ2+1315.R-5’GGC GGT CTC CAC TGA GAA TA-3’.
For mCbfa1/Runx2, amplification by PCR was performed at thermal cycling parameters of 94°C for 30 s, 60°C for 30 s and 72°C for 30 s for 34 cycles followed by a final extension at 72°C for 7 min. For mPPARγ2, amplification was carried out with 30 cycles of 94°C for 15 s, 50°C for 15 s and 65°C for 30 s followed by a final extension at 72°C for 2 min. For each PCR product mixture, 5 μl was analyzed by electrophoresis in 3% (w/v) agarose gels. The amplified DNA fragments were visualized by staining with ethidium bromide. Photographs were scanned using a ScanJet II cx (Hewlett Packard, Calif., USA). Relative quantitative data was obtained using ImageQuant Software (Molecular Dynamics, Aunnyvale, Calif., USA). Quantitative differences were normalized with the QuantumRNA 18S PCR products (Ambion, Austin, Tex., USA).
Transient reporter gene assays
D1 cells at a density of 3×105 per well in six-well culture plates were maintained in culture media until they reached 60–80% confluence. Cells were co-transfected with two DNA constructs: (1) human osteocalcin promoter luciferase-fusion plasmid (phOC-luc; 3 μg), and (2) pSV β-gal plasmid (0.5 μg), using a DOSPER Liposomal Transfection protocol (Roche, Boehringer Mannheim). The cells were transfected with 60 μl DOSPER/DNA complexes for 6 h in 1 ml fresh culture medium without serum and maintained in culture for an additional 24–48 h in complete growth media. Luciferase activity was measured using a luciferase assay kit (Promega, Madison, Wisc., USA) and luminescence was detected with an Optocom I luminometer (MGM Instruments, Cambridge, Mass., USA). β-Galactosidase activity was measured with a commercial kit using a colorimetric assay (Promega). Luciferase activity was normalized against β-galactosidase activity.
VEGF assay
Cell culture supernatants were collected at 12, 24 and 48 h for the time-course studies with 10−7 mol/l dexamethasone, or after 24 h for the dose-response studies with 10−9 mol/l, 10−7 mol/l, 1−5 mol/l dexamethasone. VEGF was measured by ELISA (R&D Systems, Minneapolis, Minn., USA), which recognizes mouse VEGF 164, the predominant isoform (cross-reactivity >95%). The detection limit of the assay was 3 pg/ml VEGF. Intra-assay coefficient of variation was 4.7%, and the inter-assay coefficient of variation was 6.4%.
Statistical methods
All experiments were performed in triplicate, and evaluated by ANOVA for statistical significance. The data are presented as the mean±SD at a significance level of P<0.05.
Results
Cells treated with increasing concentrations of dexamethasone, from 10−9 to 10−5 mol/l, accumulated lipid vesicles that were small initially and increased in size with time. The lipid vesicles were clearly distinguishable from the surrounding cells by phase contrast microscopy (Fig. 1) and with Sudan IV, a stain that is characteristic of neutral lipid in fat cells. Adipogenic changes were not found in D1 cells that were not treated with dexamethasone.
Dexamethasone increases PPARγ2 mRNA
To determine the effect of different concentrations of dexamethasone on PPARγ2 mRNA, D1 cells were incubated for 48 h with dexamethasone concentrations from 10−9 to 10−5 mol/l. Gene expression was quantified by RT-PCR analysis and is presented graphically in Fig. 2A. Within the range of dexamethasone concentrations used in our study, PPARγ2 mRNA levels increased to between 121% and 235% of controls (Fig. 2A). The increase was significant from 10−8 mol/l to 10−5 mol/l dexamethasone treatment (P<0.05), while there was no significant PPARγ2 mRNA expression increase with 10−9 mol/l dexamethasone treatment (P>0.05). To examine the time course effect, RNA was prepared from D1 cells after culture in the presence of 10−7 mol/l dexamethasone for 12 h and 1, 2, and 4 days, and compared with non-treated control cells at the same time points. Analysis by RT-PCR (Fig. 2B) showed a significant increase in PPARγ2 mRNA at 12 h (P<0.05), and further increases through the final time point of 4 days. At this time, PPARγ2 mRNA had increased to approximately 190% of control levels (P<0.05).
Dexamethasone down-regulates Cbfa1 mRNA
To determine Cbfa1/Runx2 mRNA in response to dexamethasone, D1 cells were incubated for 48 h with concentrations of 10−9 to 10−5 mol/l dexamethasone and analyzed by RT-PCR (Fig. 3A). With 10−9 mol/l dexamethasone, the level of Cbfa1/Runx2 mRNA was essentially the same as in non-treated control cells (P>0.05), while treatment with 10−8 mol/l dexamethasone decreased Cbfa1/Runx2 mRNA significantly to around 85% of control (P<0.05). At 10−7 to 10−5 mol/l dexamethasone treatment, expression of Cbfa1/Runx2 mRNA was approximately 50% of the untreated control cells (P<0.05) (Fig. 3A). To examine the time course of down-regulation of Cbfa1/Runx2 mRNA, RNA was prepared from D1 cells after culture in the presence of 10−7 mol/l dexamethasone for 12 h and 1, 2, and 4 days, and from non-treated control cells at the same time points. Analysis by RT-PCR showed that a small decrease in Cbfa1/Runx2 mRNA (to 75% of the control cells) at 12 h (P<0.05), and a further decrease through the final time point of 4 days to 47% of control levels (Fig. 3B) (P<0.05).
Dexamethasone decreases activity of the osteocalcin promoter
To characterize the inhibitory effect on osteoblastic transactivation potential of dexamethasone, we studied the effect of dexamethasone on osteocalcin promoter activity. Treatment of cells with 10−7 mol/l dexamethasone resulted in a significant decrease in osteocalcin promoter activity (P<0.05) at 1–3 days (Table 1).
Dexamethasone decreases VEGF
To investigate the effect of dexamethasone on VEGF gene expression, D1 cells were treated with dexamethasone concentrations from 10−9 to 10—5 mol/l. Cell culture supernatants were collected at 12, 24, and 48 h for the time-course study and at 24 h for the comparison of the effect of different concentrations of dexamethasone. A concentration-dependent inhibition effect was detected after 24 h of treatment with dexamethasone (Fig. 4A). VEGF decreased by 30% within 24 h of exposing the cells to dexamethasone and by 55% after 48 h (Fig. 4B).
Discussion
The increased use of steroids for immunosuppression after organ transplantation, as treatment for rheumatoid diseases and severe adult respiratory syndrome (SARS), and for chemotherapy, has resulted in an increased risk of osteonecrosis [33]. Glucocorticoids have been the focus of studies on the pathogenesis of osteonecrosis. Although statistical data show that steroids may be implicated in one-third of all cases of osteonecrosis [34], the precise mechanism of action of the steroids on cells has not been determined [19,20] to our knowledge.
We have demonstrated previously that the multipotential bone marrow cell line D1 responds to treatment with dexamethasone by differentiating into fat cells and by expressing an adipose-specific gene, 422(aP2), that increases with higher doses and prolonged treatment. There are also reports that glucocorticoids affect osteoblasts by down-regulating type-I collagen and osteocalcin gene expression [35] and inducing osteoblast and osteocyte apopotosis [36,37]. Dexamethasone has also been reported to promote the expression of markers of the osteoblast phenotype in cultures of rat marrow stromal fibroblasts [38]. Glucocorticoids can have various effects on bone cells, depending on the state of cellular differentiation, animal species, and the dose and duration of treatment [39]. The effect on human marrow cells and mouse cells is to inhibit matrix synthesis. Consistent with other reports [16,40,41], our results demonstrate that dexamethasone down-regulates the expression of Cbfa1/Runx2 and osteocalcin promoter activity while it increases the expression of PPARγ2. The previously unexplained effects of glucocorticoids on bone loss may result from down-regulation of osteoblast transcription factor expression with concomitant up-regulation of the adipocyte transcription factor, leading to the differentiation of bone marrow stromal cells along the adipocytic lineage. Since adipocytes and osteoblasts share a common pool of progenitor cells, when exogenous stimulators shift the differentiation of marrow stem cells into the adipocyte lineage, the osteoprogenitor cell pool may not be sufficient to provide enough osteoblasts in order to meet the need for bone remodeling, fracture healing, or repair of necrotic bone. In addition, marrow stem cells that have already differentiated into osteoblasts would develop apoptotic changes [36,42] on treatment with glucocorticoids, accounting for the decline in bone formation and trabecular width. Thus, decreased production of osteoblasts and accumulation of apoptotic osteocytes may contribute to osteonecrosis eventually. Furthermore, the increase in volume of fatty marrow with a concomitant increase in intraosseous pressure could decrease blood flow in a semi-intact osseous compartment, eventually leading to ischemia and osteonecrosis [18].
Blood vessels are present in each bone multicellular unit (BMU). The vessels are located in the center of the BMU between the osteoclasts advancing at the end of the cavity and the osteoblasts lining the walls farther behind. Since the capillaries in bone grow at the same rate as the BMU advances, angiogenesis, the formation of new vessels from pre-existing capillaries, might be an integral process during bone remodeling and the sequential expression of peptides during angiogenesis might have a strong impact on the mechanism of coupling of bone resorption and bone formation.
VEGF is a key regulator of vasculogenesis in the embryo and angiogenesis in adult tissues. Impaired VEGF expression has been reported in some diseases that are related to angiogenic disorders such as diabetic retinopathy, fibrovascular disease and tumor growth. An important physiological role for VEGF in bone was reported by Gerber et al. [29], as blocking VEGF-mediated capillary invasion inhibited both bone formation and resorption in the growth plate. More recent evidence indicates that expression of VEGF is important for normal endochondral bone development, not only to mediate bone vascularization but also to allow normal differentiation of hypertrophic chondrocytes, osteoblasts and osteoclasts [24,37,43]. VEGF is expressed in the normal rat tibia. Additionally, VEGF expression in osteoblasts and osteoblast-like cells is increased by several cytokines and growth factors, including prostaglandin E1 (PGE1) and PGE2, insulin-like growth factor (IGF), platelet-derived growth factor, and 1,2,3-dihydroxyvitamin D3 [44,45,46]. The VEGF gene has been reported to have 5’ AP-1 binding sites. AP-1, a dimeric transcription factor composed of the Fos and Jun proteins, has been shown to be potently inhibited by dexamethasone [47]. Down-regulation of VEGF expression by dexamethasone has previously been demonstrated in rat glioma cells [48], human vascular smooth muscle cells [49], mouse and rat pituitary folliculostellate cells [50] and porcine brain endothelial cells [51]. Dexamethasone has been shown to block prostaglandin stimulation of VEGF production in osteoblastic cells [44]. In vitro, dexamethasone produced a dose-dependent inhibition of TGF-β1-induced VEGF protein production and this observation may provide an additional explanation for the well-documented phenomenon of both impaired fracture vascularization and healing in glucocorticoid-treated patients.
In this study, we have demonstrated that the decrease in VEGF upon treatment with dexamethasone is both dose and time dependent. Down-regulation of VEGF by glucocorticoids is directly responsible for disturbed angiogenesis, resulting in the observed defects in capillary architecture, which eventually lead to osteonecrosis. It is suggested that the mechanism of steroid-induced necrosis is through the inhibition of angiogenesis by suppressing VEGF.
In conclusion, there may be at least two mechanisms that are involved in the pathogenesis of osteonecrosis. First, glucocorticoids down-regulate osteoblast transcription factor gene expression and, by up-regulating adipocyte transcription factor gene expression, could lead to the differentiation of bone marrow stromal cells along the adipocytic lineage. Second, glucocorticoids decrease angiogenesis by suppressing VEGF. Consequently, the action of glucocorticoids may impair mesenchymal cell differentiation and thereby decrease blood supply leading to bone cell death.
References
Wang GJ, Cui Q, Balian G (2000) The Nicolas Andry award. The pathogenesis and prevention of steroid-induced osteonecrosis. Clin Orthop 295–310
Glueck CJ, Freiberg RA, Wang P (2003) Role of thrombosis in osteonecrosis. Curr Hematol Rep 2:417–422
Boss JH,Misselevich I (2003) Osteonecrosis of the femoral head of laboratory animals: the lessons learned from a comparative study of osteonecrosis in man and experimental animals. Vet Pathol 40:345–354
Moens P,Fabry G (2003) Legg-Calve-Perthes disease: one century later. Acta Orthop Belg 69:97–103
Stulberg BN (2003) Osteonecrosis: what to do, what to do! J Arthroplasty 18:74–79
Cui Q, Wang GJ, Balian G (1997) Steroid-induced adipogenesis in a pluripotential cell line from bone marrow. J Bone Joint Surg [Am] 79:1054–1063
Karsenty G, Ducy P, Starbuck M, Priemel M, Shen J, Geoffroy V, Amling M (1999) Cbfa1 as a regulator of osteoblast differentiation and function. Bone 25:107–108
Li X, Cui Q, Kao C, Wang GJ, Balian G (2003) Lovastatin inhibits adipogenic and stimulates osteogenic differentiation by suppressing PPARgamma2 and increasing Cbfa1/Runx2 expression in bone marrow mesenchymal cell cultures. Bone 33:652–659
Franceschi RT, Xiao G (2003) Regulation of the osteoblast-specific transcription factor, Runx2: responsiveness to multiple signal transduction pathways. J Cell Biochem 88:446–454
Karsenty G (1999) The genetic transformation of bone biology. Genes Dev 13:3037–3051
Shui C, Spelsberg TC, Riggs BL, Khosla S (2003) Changes in Runx2/Cbfa1 expression and activity during osteoblastic differentiation of human bone marrow stromal cells. J Bone Miner Res 18:213–221
Komori T, Yagi H, Nomura S, Yamaguchi A, Sasaki K, Deguchi K, Shimizu Y, Bronson RT, Gao YH, Inada M, Sato M, Okamoto R, Kitamura Y, Yoshiki S, Kishimoto T (1997) Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 89:755–764
Ducy P, Zhang R, Geoffroy V, Ridall AL, Karsenty G (1997) Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell 89:747–754
Mueller E, Drori S, Aiyer A, Yie J, Sarraf P, Chen H, Hauser S, Rosen ED, Ge K, Roeder RG, Spiegelman BM (2002) Genetic analysis of adipogenesis through peroxisome proliferator-activated receptor gamma isoforms. J Biol Chem 277:41925–41930
Shao D,Lazar MA (1997) Peroxisome proliferator activated receptor gamma, CCAAT/enhancer-binding protein alpha, and cell cycle status regulate the commitment to adipocyte differentiation. J Biol Chem 272:21473–21478
Shi X, Chang Z, Blair H, McDonald J, Cao X (1998) Glucocorticoids induce adipogenesis of stromal cells by transcriptionally activating PPAR. Bone 23:S454
Jones JP Jr (1999) Coagulopathies and osteonecrosis. Acta Orthop Belg 65 (Suppl 1):5–8
Hungerford DS,Lennox DW (1985) The importance of increased intraosseous pressure in the development of osteonecrosis of the femoral head: implications for treatment. Orthop Clin N Am 16:635–654
Jones LC, Mont MA, Le TB, Petri M, Hungerford DS, Wang P, Glueck CJ (2003) Procoagulants and osteonecrosis. J Rheumatol 30:783
Jones JP Jr (2001) Alcoholism, hypercortisonism, fat embolism and osseous avascular necrosis. Clin Orthop 393:4–12
Wang GJ (1987) The Frank Stinchfield Award paper. Improvement of femoral head blood flow in steroid-treated rabbits using lipid-clearing agent. Hip 87–93
Colnot CI, Helms JA (2001) A molecular analysis of matrix remodeling and angiogenesis during long bone development. Mech Dev 100:245–250
Parfitt AM (2000) The mechanism of coupling: a role for the vasculature. Bone 26:319–323
Streeten EA,Brandi ML (1990) Biology of bone endothelial cells. Bone Miner 10:85–94
Colnot C, Thompson Z, Miclau T, Werb Z, Helms JA (2003) Altered fracture repair in the absence of MMP9. Development 130:4123–4133
Fong KD, Nacamuli RP, Loboa EG, Henderson JH, Fang TD, Song HM, Cowan CM, Warren SM, Carter DR, Longaker MT (2003) Equibiaxial tensile strain affects calvarial osteoblast biology. J Craniofac Surg 14:348–355
Furumatsu T, Shen ZN, Kawai A, Nishida K, Manabe H, Oohashi T, Inoue H, Ninomiya Y (2003) Vascular endothelial growth factor principally acts as the main angiogenic factor in the early stage of human osteoblastogenesis. J Biochem (Tokyo) 133:633–639
Tatsuyama K, Maezawa Y, Baba H, Imamura Y, Fukuda M (2000) Expression of various growth factors for cell proliferation and cytodifferentiation during fracture repair of bone. Eur J Histochem 44:269–278
Gerber HP, Vu TH, Ryan AM, Kowalski J, Werb Z, Ferrara N (1999) VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat Med 5:623–628
Diduch DR, Coe MR, Joyner C, Owen ME, Balian G (1993) Two cell lines from bone marrow that differ in terms of collagen synthesis, osteogenic characteristics, and matrix mineralization. J Bone Joint Surg [Am] 75:92–105
Sur S, Gleich G, Bolander M (1995) Comparative evaluation of quantitative PCR methods. Methods in Neurosciences 26:147–160
de Leeuw WJ, Slagboom PE, Vijg J (1989) Quantitative comparison of mRNA levels in mammalian tissues: 28S ribosomal RNA level as an accurate internal control. Nucl Acids Res 17:10137–10138
Bradbury G, Benjamin J, Thompson J, Klees E, Copeland J (1994) Avascular necrosis of bone after cardiac transplantation. Prevalence and relationship to administration and dosage of steroids. J Bone Joint Surg [Am] 76:1385–1388
Arlet J (1992) Nontraumatic avascular necrosis of the femoral head. Past, present, and future. Clin Orthop 277:12–21
Canalis E,Delany AM (2002) Mechanisms of glucocorticoid action in bone. Ann N Y Acad Sci 966:73–81
O’Brien CA, Jia D, Plotkin LI, Bellido T, Powers CC, Stewart SA, Manolagas SC, Weinstein RS (2004) Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology 145:1835–1841
Maes C, Carmeliet P, Moermans K, Stockmans I, Smets N, Collen D, Bouillon R, Carmeliet G (2002) Impaired angiogenesis and endochondral bone formation in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. Mech Dev 111:61–73
Leboy PS, Beresford JN, Devlin C, Owen ME (1991) Dexamethasone induction of osteoblast mRNAs in rat marrow stromal cell cultures. J Cell Physiol 146:370–378
Pockwinse SM, Stein JL, Lian JB, Stein GS (1995) Developmental stage-specific cellular responses to vitamin D and glucocorticoids during differentiation of the osteoblast phenotype: interrelationship of morphology and gene expression by in situ hybridization. Exp Cell Res 216:244–260
Lecka-Czernik B, Gubrij I, Moerman EJ, Kajkenova O, Lipschitz DA, Manolagas SC, Jilka RL (1999) Inhibition of Osf2/Cbfa1 expression and terminal osteoblast differentiation by PPARgamma2. J Cell Biochem 74:357–371
Manolagas SC,Weinstein RS (1999) New developments in the pathogenesis and treatment of steroid-induced osteoporosis. J Bone Miner Res 14:1061–1066
Weinstein RS, Jia D, Powers CC, Stewart SA, Jilka RL, Parfitt AM, Manolagas SC (2004) The skeletal effects of glucocorticoid excess override those of orchidectomy in mice. Endocrinology 145:1980–1987
Zelzer E, McLean W, Ng YS, Fukai N, Reginato AM, Lovejoy S, D’Amore PA, Olsen BR (2002) Skeletal defects in VEGF(120/120) mice reveal multiple roles for VEGF in skeletogenesis. Development 129:1893–1904
Harada S, Nagy JA, Sullivan KA, Thomas KA, Endo N, Rodan GA, Rodan SB (1994) Induction of vascular endothelial growth factor expression by prostaglandin E2 and E1 in osteoblasts. J Clin Invest 93:2490–2496
Goad DL, Rubin J, Wang H, Tashjian AH, Jr., Patterson C (1996) Enhanced expression of vascular endothelial growth factor in human SaOS-2 osteoblast-like cells and murine osteoblasts induced by insulin-like growth factor I. Endocrinology 137:2262–2268
Wang DS, Yamazaki K, Nohtomi K, Shizume K, Ohsumi K, Shibuya M, Demura H, Sato K (1996) Increase of vascular endothelial growth factor mRNA expression by 1,25-dihydroxyvitamin D3 in human osteoblast-like cells. J Bone Miner Res 11:472–479
Jonat C, Rahmsdorf HJ, Park KK, Cato AC, Gebel S, Ponta H, Herrlich P (1990) Antitumor promotion and antiinflammation: down-modulation of AP-1 (Fos/Jun) activity by glucocorticoid hormone. Cell 62:1189–1204
Heiss JD, Papavassiliou E, Merrill MJ, Nieman L, Knightly JJ, Walbridge S, Edwards NA, Oldfield EH (1996) Mechanism of dexamethasone suppression of brain tumor-associated vascular permeability in rats. Involvement of the glucocorticoid receptor and vascular permeability factor. J Clin Invest 98:1400–1408
Nauck M, Karakiulakis G, Perruchoud AP, Papakonstantinou E, Roth M (1998) Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells. Eur J Pharmacol 341:309–315
Gloddek J, Pagotto U, Paez PM, Arzt E, Stalla GK, Renner U (1999) Pituitary adenylate cyclase-activating polypeptide, interleukin-6 and glucocorticoids regulate the release of vascular endothelial growth factor in pituitary folliculostellate cells. J Endocrinol 160:483–490
Fischer S, Renz D, Schaper W, Karliczek GF (2001) In vitro effects of dexamethasone on hypoxia-induced hyperpermeability and expression of vascular endothelial growth factor. Eur J Pharmacol 411:231–243
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Li, X., Jin, L., Cui, Q. et al. Steroid effects on osteogenesis through mesenchymal cell gene expression. Osteoporos Int 16, 101–108 (2005). https://doi.org/10.1007/s00198-004-1649-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00198-004-1649-7